Skip to main content
SpringerLink
Log in

Antifungal Agents

  • Chapter
  • First Online:
Infections in Hematology

  • 1589 Accesses

Abstract

This chapter serves as a review of currently available antifungals administered via the enteral, intravenous, or inhalational route. The greater number of antifungal medications now available necessitates a detailed knowledge of each drug class. Amphotericin B deoxycholate and the lipid formulations, fluconazole, itraconazole, posaconazole, voriconazole, caspofungin, micafungin, anidulafungin, and flucytosine will be discussed. Emphasis is placed on pharmacodynamics and kinetics, drug interactions, adverse events, and evidence for their use including differences in their spectrum of activity. Selected clinical trials demonstrating the efficacy of these agents will also be reviewed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Chamilos G, Luna M, Lewis RE, et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989–2003). Haematologica. 2006;91(7):986–9.

    PubMed  Google Scholar 

  2. Pappas PG, Alexander BD, Andes DR, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis. 2010;50(8):1101–11.

    Article  PubMed  Google Scholar 

  3. Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis. 2010;50(8):1091–100.

    Article  PubMed  Google Scholar 

  4. Pagano L, Caira M, Candoni A, et al. Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. Haematologica. 2010;95(4):644–50.

    Article  PubMed Central  PubMed  Google Scholar 

  5. Leventakos K, Lewis RE, Kontoyiannis DP. Fungal infections in leukemia patients: how do we prevent and treat them? Clin Infect Dis. 2010;50(3):405–15.

    Article  PubMed  Google Scholar 

  6. Andes D. In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis. Antimicrob Agents Chemother. 2003;47(4):1179–86.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  7. Rex JH, Pfaller MA. Has antifungal susceptibility testing come of age? Clin Infect Dis. 2002;35(8):982–9.

    Article  CAS  PubMed  Google Scholar 

  8. Saag MS, Graybill RJ, Larsen RA, et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis. 2000;30(4):710–8.

    Article  CAS  PubMed  Google Scholar 

  9. Dodds Ashley ES, Lewis R, Lewis JS, Martin C, Andes D. Pharmacology of systemic antifungal agents. Clin Infect Dis. 2006;43(s1):S28–39.

    Article  CAS  Google Scholar 

  10. Pappas PG, Rex JH, Sobel JD, et al. Guidelines for treatment of candidiasis. Clin Infect Dis. 2004;38(2):161–89.

    Article  PubMed  Google Scholar 

  11. Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med. 2002;346(4):225–34.

    Article  CAS  PubMed  Google Scholar 

  12. Goldberg E, Gafter-Gvili A, Robenshtok E, Leibovici L, Paul M. Empirical antifungal therapy for patients with neutropenia and persistent fever: systematic review and meta-analysis. Eur J Cancer. 2008;44(15):2192–203.

    Article  CAS  PubMed  Google Scholar 

  13. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347(6):408–15.

    Article  CAS  PubMed  Google Scholar 

  14. Walsh TJ, Anaissie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46(3):327–60.

    Article  CAS  PubMed  Google Scholar 

  15. Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis. 2008;47(4):503–9.

    Article  PubMed  Google Scholar 

  16. Cornely OA, Maertens J, Bresnik M, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis. 2007;44(10):1289–97.

    Article  CAS  PubMed  Google Scholar 

  17. Rijnders BJ, Cornelissen JJ, Slobbe L, et al. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis. 2008;46(9):1401–8.

    Article  CAS  PubMed  Google Scholar 

  18. Borro JM, Sole A, de la Torre M, et al. Efficiency and safety of inhaled amphotericin B lipid complex (abelcet) in the prophylaxis of invasive fungal infections following lung transplantation. Transplant Proc. 2008;40(9):3090–3.

    Article  CAS  PubMed  Google Scholar 

  19. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. 2002;347(25):2020–9.

    Article  CAS  PubMed  Google Scholar 

  20. Saliba F, Dupont B. Renal impairment and amphotericin B formulations in patients with invasive fungal infections. Med Mycol. 2008;46(2):97–112.

    Article  CAS  PubMed  Google Scholar 

  21. Kleinberg M. What is the current and future status of conventional amphotericin B? Int J Antimicrob Agents. 2006;27 Suppl 1:12–6.

    Article  PubMed  Google Scholar 

  22. Kramer MR, Marshall SE, Denning DW, et al. Cyclosporine and itraconazole interaction in heart and lung transplant recipients. Ann Intern Med. 1990;113(4):327–9.

    Article  CAS  PubMed  Google Scholar 

  23. Varis T, Kaukonen KM, Kivisto KT, Neuvonen PJ. Plasma concentrations and effects of oral methylprednisolone are considerably increased by itraconazole. Clin Pharmacol Ther. 1998;64(4):363–8.

    Article  CAS  PubMed  Google Scholar 

  24. Tucker RM, Denning DW, Hanson LH, et al. Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. Clin Infect Dis. 1992;14(1):165–74.

    Article  CAS  PubMed  Google Scholar 

  25. Kivisto KT, Lamberg TS, Kantola T, Neuvonen PJ. Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole. Clin Pharmacol Ther. 1997;62(3):348–54.

    Article  CAS  PubMed  Google Scholar 

  26. Engels FK, Ten Tije AJ, Baker SD, et al. Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel. Clin Pharmacol Ther. 2004;75(5):448–54.

    Article  CAS  PubMed  Google Scholar 

  27. Grub S, Bryson H, Goggin T, Ludin E, Jorga K. The interaction of saquinavir (soft gelatin capsule) with ketoconazole, erythromycin and rifampicin: comparison of the effect in healthy volunteers and in HIV-infected patients. Eur J Clin Pharmacol. 2001;57(2):115–21.

    Article  CAS  PubMed  Google Scholar 

  28. Jeng MR, Feusner J. Itraconazole-enhanced vincristine neurotoxicity in a child with acute lymphoblastic leukemia. Pediatr Hematol Oncol. 2001;18(2):137–42.

    Article  CAS  PubMed  Google Scholar 

  29. Noxafil (posaconazole) [package insert]. Kenilworth: Schering Corp; 2006.

    Google Scholar 

  30. Sporanox (itraconazole) [package insert]. Toronto: Janssen-Ortho; 2001.

    Google Scholar 

  31. VFEND (voriconazole) [package insert]. Roering: Pfizer; 2008.

    Google Scholar 

  32. Stevens DA, Diaz M, Negroni R, et al. Safety evaluation of chronic fluconazole therapy. Fluconazole Pan-American Study Group. Chemotherapy. 1997;43(5):371–7.

    Article  CAS  PubMed  Google Scholar 

  33. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation–a prospective, randomized, double-blind study. J Infect Dis. 1995;171(6):1545–52.

    Article  CAS  PubMed  Google Scholar 

  34. Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis. 2010;50(3):291–322.

    Article  PubMed  Google Scholar 

  35. Jaruratanasirikul S, Kleepkaew A. Influence of an acidic beverage (Coca-Cola) on the absorption of itraconazole. Eur J Clin Pharmacol. 1997;52(3):235–7.

    Article  CAS  PubMed  Google Scholar 

  36. Lange D, Pavao JH, Wu J, Klausner M. Effect of a cola beverage on the bioavailability of itraconazole in the presence of H2 blockers. J Clin Pharmacol. 1997;37(6):535–40.

    Article  CAS  PubMed  Google Scholar 

  37. Van de Velde VJ, Van Peer AP, Heykants JJ, et al. Effect of food on the pharmacokinetics of a new hydroxypropyl-beta-cyclodextrin formulation of itraconazole. Pharmacotherapy. 1996;16(3):424–8.

    PubMed  Google Scholar 

  38. Wheat LJ, Freifeld AG, Kleiman MB, et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis. 2007;45(7):807–25.

    Article  PubMed  Google Scholar 

  39. De Beule K, Van Gestel J. Pharmacology of itraconazole. Drugs. 2001;61 Suppl 1:27–37.

    Article  PubMed  Google Scholar 

  40. Ahmad SR, Singer SJ, Leissa BG. Congestive heart failure associated with itraconazole. Lancet. 2001;357(9270):1766–7.

    Article  CAS  PubMed  Google Scholar 

  41. Glasmacher A, Cornely O, Ullmann AJ, et al. An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia. J Antimicrob Chemother. 2006;57(2):317–25.

    Article  CAS  PubMed  Google Scholar 

  42. Marr KA, Crippa F, Leisenring W, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood. 2004;103(4):1527–33.

    Article  CAS  PubMed  Google Scholar 

  43. Winston DJ, Maziarz RT, Chandrasekar PH, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med. 2003;138(9):705–13.

    Article  CAS  PubMed  Google Scholar 

  44. Courtney R, Pai S, Laughlin M, Lim J, Batra V. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother. 2003;47(9):2788–95.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  45. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356(4):348–59.

    Article  CAS  PubMed  Google Scholar 

  46. Ullmann AJ, Lipton JH, Vesole DH, et al. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007;356(4):335–47.

    Article  CAS  PubMed  Google Scholar 

  47. Sansone-Parsons A, Krishna G, Calzetta A, et al. Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers. Antimicrob Agents Chemother. 2006;50(5):1881–3.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  48. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis. 2003;36(5):630–7.

    Article  CAS  PubMed  Google Scholar 

  49. Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, Kleinermans D. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother. 2002;46(8):2546–53.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  50. Lazarus HM, Blumer JL, Yanovich S, Schlamm H, Romero A. Safety and pharmacokinetics of oral voriconazole in patients at risk of fungal infection: a dose escalation study. J Clin Pharmacol. 2002;42(4):395–402.

    Article  CAS  PubMed  Google Scholar 

  51. Ikeda Y, Umemura K, Kondo K, Sekiguchi K, Miyoshi S, Nakashima M. Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status. Clin Pharmacol Ther. 2004;75(6):587–8.

    Article  CAS  PubMed  Google Scholar 

  52. Walsh TJ, Driscoll T, Milligan PA, et al. Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children. Antimicrob Agents Chemother. 2010;54(10):4116–23.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  53. Zonios DI, Gea-Banacloche J, Childs R, Bennett JE. Hallucinations during voriconazole therapy. Clin Infect Dis. 2008;47(1):e7–10.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  54. Pfaller MA, Diekema DJ, Ostrosky-Zeichner L, et al. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J Clin Microbiol. 2008;46(8):2620–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  55. Kuse ER, Chetchotisakd P, da Cunha CA, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet. 2007;369(9572):1519–27.

    Article  CAS  PubMed  Google Scholar 

  56. Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med. 2007;356(24):2472–82.

    Article  CAS  PubMed  Google Scholar 

  57. Pappas PG, Rotstein CM, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis. 2007;45(7):883–93.

    Article  CAS  PubMed  Google Scholar 

  58. Heinz WJ, Einsele H. Caspofungin for treatment of invasive aspergillus infections. Mycoses. 2008;51 Suppl 1:47–57.

    Article  CAS  PubMed  Google Scholar 

  59. Polak A, Scholer HJ. Mode of action of 5-fluorocytosine and mechanisms of resistance. Chemotherapy. 1975;21(3–4):113–30.

    Article  CAS  PubMed  Google Scholar 

  60. Stamm AM, Diasio RB, Dismukes WE, et al. Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. Am J Med. 1987;83(2):236–42.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Microbiology and Immunology, Coccidioidomycosis Serology Laboratory, University of California – Davis, One Shields Avenue, Tupper Hall, Davis, CA, 95616, USA

    George R. Thompson III

  2. Division of Infectious Diseases, Department of Internal Medicine, University of California Davis Medical Center, 4150 V Street, Suite G500, Sacramento, CA, 95817, USA

    George R. Thompson III

  3. Division of Infectious Diseases, Department of Internal Medicine, University of Texas Health Science Center at San Antonio and South Texas Veterans Health Care System, San Antonio, TX, 78229, USA

    Thomas F. Patterson

Authors
  1. George R. Thompson III
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas F. Patterson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to George R. Thompson III .

Editor information

Editors and Affiliations

  1. Department of Hematology, Oncology and Palliative Care, Klinikum Ernst von Bergmann, Potsdam, Germany

    Georg Maschmeyer

  2. Department of Infectious Diseases, Infection Control and Employee Health, M.D. Anderson Cancer Center University of Texas, Houston, Texas, USA

    Kenneth V.I. Rolston

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Thompson, G.R., Patterson, T.F. (2015). Antifungal Agents. In: Maschmeyer, G., Rolston, K. (eds) Infections in Hematology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-44000-1_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-44000-1_15

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-43999-9

  • Online ISBN: 978-3-662-44000-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation